INTRODUCTION
Targeted therapies according to the lung tumors' genetic mutations are already on the market and have been approved for first line treatment. [1] [2] [3] At the same time, additional pathways are being investigated as possible treatment approaches. [4] [5] [6] [7] [8] However, the major limitation of the targeted therapy still remains the limited number of patients with the genetic mutations that have been investigated. Therefore, doublet chemotherapy still remains the cornerstone of the basic treatment modality for advanced stage lung cancer. Another aspect of chemotherapy treatment that has also to be defined is what should be considered second cycle of chemotherapy and what maintenance. 9 Current intravenous doublet chemotherapy administration still remains toxic for the several cells lines of the human body other than the tumor cells, and therefore systematic adverse effects are observed in several lung cancer patients. 10, 11 The concept of locoregional administration either as chemotherapy alone, immunotherapy or gene therapy has been investigated in lung cancer, [12] [13] [14] [15] [16] [17] and in several other organs. [18] [19] [20] The major objective was to investigate whether locoregional administration would present less systematic side effects. Chemotherapy drugs still have the major disadvantage of having no specific target cell; therefore, all cell with a fast division rate are affected. Current pharmaceuticals targeting the genome of lung tumor have the limitation that the genetic pathways investigated are found in a small number of lung cancer patients. Therefore, an effort has been made to target the lung cancer tumor with gene therapy either in a mode to sensitize the tumor to radiotherapy or to chemotherapy. Moreover, suicide gene therapy has been applied to convert a harmless drug to lethal only for cancer cells. 14, 21, 22 Gene therapy is actually the modality where genetic material is transfer into a cell. Aerosol gene therapy has been investigated in several studies. [23] [24] [25] [26] [27] [28] In order for the genetic material to be delivered into the target cell, a vehicle is used: (a) the viral and (b) nonviral vector. The viral vector efficiently delivers the gene to the target cell; however, it tends to formulate neutralizing antibodies, immunomodulatory and inflammatory adverse reactions within a period of 3-7 days depending of viral vector. 29 On the other hand it has been presented in previous studies that the nonviral vectors bind more efficiently to the airway epithelium; however, safety issues are still under investigation. To enhance transport of the nonviral vector/DNA complex to the cell-surface active transport by incorporating elements such as integrins and carbohydrate elements has been investigated. 30, 31 Regarding aerosol gene therapy, the following pathways have been investigated either as inhibition: (a) K-Ras, (b) epidermal growth factor and (c) antivascular endothelial growth factor or as immune therapy.
The nonviral vectors that have been used until now can be summarized; (a) polyethyleneimine (PEI), 35 ultrafiltrated PEI (pCIKLux/PEI), 36 large glucosylated PEI, 33 PEI/polyethylene glycol, 37 protamine-L-polysine and PEI, 24 dry powder PEI, 38 (b) tetrafunctional amphiphilic block copolymer 704, 39 (c) dTAT-PEI, 40 (d) liposome vector (DHDTMA/DOPE), 41 adenovirus vector-liposome F-AL-Ad5, 42 (e) imidazole ring-containing urocanic acid-modified chitosan, 43 chitosan-fibronectin attachment protein of mycobacterium bovis (FAP-B), 44 (f), solvoplex, 45 (g) cationic phosphonolipids 46 and (h) biodegradable PEI 47 (Table 1) . Aerosol delivery of nonviral vectors has the disadvantage that shear forces during nebulization divide the vector/DNA complex, and until now only air-jet nebulizers have been used in experimental protocols. 48, 49 In the current study, we wanted to test the safety of the new nonviral vector 2-diethylaminoethyl-dextran methyl methacrylate copolymer (DDMC) by Ryuyju Science Corporation, which belongs to the 2-diethylaminoethyl-dextran (DAEX) family. The novel nonviral vector DDMC was synthesized by graft polymerization of methyl methacrylate onto DAEX. These copolymers with their hydrophilic and hydrophobic regions, have high transfection efficiency and can be sterilized by autoclaving. 50 Further investigation with DDMC/DNA has presented in vitro higher transfection efficiency in COS-7 cell lines, 51 in comparison with DAEX/DNA in HEK293 cell lines. 52 DDMC has efficient absorbing capability both for RNA and DNA. This is attributed to the cationic property and has been found to be influenced by pH and ionic strengths. 53 The DDMC/DNA formation reaction is influenced by the Coulomb forces and hydrophobic bonding strength, as well as the hydrogen bonding strength attributed to the hydrophobicity of the grafted methyl methacrylate sections. In addition, optimal cell affinity has been observed. 54 The properties of the DDMC/DNA and gene transfection are still under investigation. 50 Herein, we present a novel method of display and safety evaluation of the novel DDMC nonviral vector with the CytoViva technique (CytoViva Inc., Auburn, AL, USA).
RESULTS

Pathology findings
Ten mice were killed after three aerosol sessions (10 days) and ten mice were killed after six aerosol administrations (21 days). All mice were first administered the aerosol mist and exactly afterwards were killed in an effort to display efficiently the diffusion of the nonviral vector molecules within the lung parenchyma with the CytoViva technique. None of the animals died before the preconcerted date. The lungs were dissected from the animals and washed with ice-cold phosphate-buffered saline and prepared in paraffin blocks. Macroscopical findings did not illustrate any abnormal findings. Macroscopic examination did not reveal any abnormal findings; however, histopathological examination revealed in group B and C emphysema lesions. The observed emphysema lesions were more severe in group C in comparison with group B; this observation indicates that the adverse effect was not transient but dose dependent with the administration of the DDMC nonviral vector (Figures 1 and 2 ). Nonviral vector display (CytoViva) Two years of preparation were required in order to set up the technique of CytoViva in order to apply it for the display of nonviral particles within the lung tissue. The CytoViva can be described as follows: optical and hyperspectral images along with hyperspectral data were captured utilizing a research grade optical microscope equipped with the CytoViva advanced darkfield illumination system, dual mode fluorescence module and integrated hyperspectral imaging system. This integrated system builds hyperspectral image files via 'push broom' method, enabling the creation of a high signal to noise spectral image file. Subsequent image analysis delineates the reflectance spectral response of the sample elements in each nanoscale pixel of the image file (Figures 3-5 ).
DISCUSSION
Multimodality approach is warranted for aerosol gene therapy. First, the system that will produce the aerosol has to be chosen carefully. Two different nebulizers have been used until now: the air-jet and ultrasonic nebulizers. Only air-jet nebulizers have been efficiently used until now, 48, 49 because the ultrasonics were evaluated with several formulations such as cationic polymers, and it was observed that their notorious energy alters/damages the vector/DNA complex. 55 Toward this direction, supercoiled minivectors 56 and self-entanglement have been investigated. 57 The nebulizer must be chosen based on the droplet size; 3-5 mm is the optimal size. In addition, aerosol gene therapy has been delivered by nebulization, 23 coarse spray with endoscopic pipe (model BA 4100S; Olympus, Sartorius, Gottingen, Germany), 58 minisprayer (penncentury; Penn-Century, Inc., Wyndmoor, PA, USA), 59 aerosol with spacer 60 instillation 59 and dry powder. 38, 61 In the study by Beck et al., 59 several aerosol gene therapy administrations are compared with scintigraphy and the information presented suggest that we still need an efficient delivery system-modality. In the case of inhaled insulin and inhaled chemotherapy, a breath actuated inlet is proposed for efficient delivery activation. 12, 62 Another method for efficient aerosol delivery was proposed with the addition of 5% CO 2 ; with the addition, tidal volume was increased by 180% and the respiratory rate was decreased subsequently the subjects had deep inhalations. 25, 34 Proper setting of the aerosol administration is crucial for efficient lung deposition. A nose-only chamber administration is more efficient than that for the whole body exposure. 63, 64 In the whole body exposure, the pharmacokinetics change as an amount of the drug concentration is absorbed from the skin. Therefore, one would have two release drug curves. An effort was made to evaluate the same complex of vector-DNA by aerosol and intravenous to evaluate the efficiency in correlation with the lung concentration. It was observed that the aerosol method had an increased concentration in the lung in shorter time, which meant higher drug concentration, and therefore efficient local disease control. 44 Taking this idea to a human model with a lung cancer patient, longer circulation of cytotoxic agents results in harmful adverse effects to normal cells.
In addition, inhaled gene therapy presents less immune response in comparison with the systemic gene therapy administration. 23 Moreover, the respiratory defense mechanisms are a major obstacle: (a) cough, (b) mucus, (c) beating cilia clearance, (d) macrophages (tracheal/alveolar) and (e) immune response (dendritic cells). The mucus in specific is a major obstacle for aerosol gene therapy in cystic fibrosis. The addition of polyethylene glycol coating resulted in a 'stealth' molecule, which as a result allows the investigated formulation to have a prolonged local site deposition and sustain release. 63 The viral vectors are the most efficient delivery vehicle; however, several disadvantages have to be addressed: (a) recombination, (b) immunogenicity and (c) oncogenic translation. 65 On the other hand, the nonviral vectors offer nonspecific ionic interaction with the airway epithelial cells, bypass the immune system, 'proton sponge effect' and prolong control release; however, safety issues have still to be addressed. 27, 28, 66 The efficiency of PEI nonviral vector is closely associated with the molecular weight. Therefore, high molecular weight 425 kDa offer higher transfection, however, also increased cytotoxicity. Therefore, several efforts were made by several groups to identify the optimal size from 2 to 25 kDa. 36, 64 Furthermore, biodegradable PEIs and crosslinked technology PEIs 47, 67 both have the property of releasing their plasmid while inducing less immune reaction and cytotoxicity.
Inhaled gene therapy has been investigated in a dry powder form. 38, 61 Dry powder has presented superiority in comparison with aqueous solutions. Several aqueous formulations are unstable; they tend to aggregate, loss of drug is observed and also lose their transfection capability. [68] [69] [70] Freeze drying lyophilization with lyoprotectants (lactose, trehalose and sucrose) and powderization have been used to produce dry powder. Sugar during lyophilization is absolutely necessary for the complex to maintain its size, indifferent of the sugar used. 38 Otherwise, the complex increases in size. An important detail is that the particles change size during lyophilization and again after powderization with excess sugar. Moreover, the z-potential is increased affected during lyophilization, but decreases after powderization and it is indifferent of the sugar. In addition, sugar as lyoprotectants does not influence the gene expression/ transfection in different cell lines. 38 Sucrose produces the finest powder in comparison with lactose and trehalose. However, an important observation has been made where lactose as excipient demonstrates higher gene delivery and gene expression in comparison with the other sugars. 71 Therefore, although the powder and mass median aerodynamic diameter have smaller values with sucrose, this does not mean that the produced dry formulation is more efficient; we do not always need small particles, but also efficient ones.
Spray drying is another technique to produce dry powder; it has the advantage of the 'one step' production; however, its disadvantage is the high thermal temperatures, absorption phenomenon and shearing stress of the molecules. Polyols and disaccharides are necessary to protect the molecules during spray drying. During the spray drying process, carbohydrates are added as thermoprotectives and finally amino acids are included as nebulization enhancers. Chitosan addition has demonstrated a slight reduction in the expression levels of luciferase. However, spray drying is an efficient method of dry powder production with a z-potential of 425 mV, spherical particles and mass median aerodynamic diameter o6 mm.
61
The aerosol aqueous solutions and dry powders have been evaluated in several airway models from mice, 34 sheep, 72 rabbits 73 and human cadaver. 58 The defense mechanisms activity differs from one model to another. The evaluation of pulmonary function tests has been previously performed with additional display of the nonviral particles in the lung tissue in multiple studies with multiple methods. 27, 28, 73 However, this is the first time that the CytoViva technique has been applied for the display of nonviral particles; the histopathological patterns are also presented in comparison with the optical and spectral image of the CytoViva technique. A formulation can induce immediate toxicity in one airway model, whereas in another even larger amounts of a toxic formulation are well tolerated. Therefore, in our experiment the DDMC as it was prepared by our group is not proper for administration in small airways; however, it still has to be evaluated for gene transfection ability. In a joint effort between our departments, we are currently evaluating a novel airway model for aerosol administration in cadaver lungs with the assistance of mechanical ventilation and blood pump connected to major vessels. A simultaneous administration is performed with the aerosol administration and absorption of the aerolized drug formulation from the blood pump.
CONCLUSIONS
Inhaled gene therapy is a noninvasive treatment modality for inherited (asthma, cystic fibrosis) and acquired (lung cancer and pulmonary fibrosis) respiratory diseases . Dry powder formulations have been observed to be patient friendly, as patient-device activation coordination is not necessary. The proper airway model is still warranted in order to properly evaluate aerosolized aqueous solutions and dry powders. Finally, with our results we want to present that although huge efforts have been made toward new nonviral vectors and local delivery systems, the issue of safety still remains. Probably, a future direction should be a multifunctional polycomplexe that targets both the genome and at the same time releases a drug formulation.
MATERIALS AND METHODS Animals
Male albino BALB/c mice, 2 months old were obtained from the experimental laboratory of the 'Theiageneio'Anticancer Hospital, Thessaloniki, Greece. In total, 30 mice were raised in the laboratory and randomly divided in three groups. The control group A were the mice to which no vector was administered, group B were the mice that had three administrations of aerosol DDMC nonviral vector (one session every 3 days) and group C were the mice that had six aerosol DDMC sessions (one session every 3 days). The mice were kept in single cages in a temperaturecontrolled room on 12 h light-dark cycle, and were allowed free access to food and water. None of the mice died for reason other than the scheduled killing to obtain the lungs for histopathological purposes. The animal care and experiment was carried out in accordance with the guidelines of the Greek National Council for Animal Experimentation (Permission number 482384/4146-13).
Nonviral vector solution preparation and aerosol droplet evaluation
The vector was purchased by Ryujyu Science Corporation, Seto-city, Aichi, Japan (by PZ and WH-S with the following contracts: EG150685513JP, EG104761376JP, EG044289073JP). The purpose of the study was first to evaluate the safety of the vector, and second upon positive results to proceed in the evaluation of the efficacy of the DDMC-p53 plasmid complex in a Lewis lung cancer BALBC mouse model. The DDMC vector belongs to the DAEX family; 50 however, it presents stability for autoclaving sterilization at 121 1C for 15 min, no serum inhibition, broad cell line range, best results with small interfering RNA applications, high efficiency by the use of low DNA amounts, excellent reproducibility, low toxicity in comparison with DEAE-dextran and a high DNase protection facility by DNase degradation. The vector was delivered in 1 ml and was diluted with 10 ml of 5% glucose solution (11 ml solution in total). The mixture was vortexed gently in order to homogenize. A Sunmist compressor nebulizer (DeVilbiss Healthcare LLC, Toledo, OH, USA) was used to aerosolize 1 ml/11 ml in 5 min for each mouse ( Figure 6 ). The size distribution of the solution droplets was determined using a Malvern Mastersizer 2000 laser scattering apparatus (Malvern, Worcestershire, UK) equipped with a Scirocco module (Malvern). The latter was modified as for the dispersion to be sprayed directly into the sample chamber, normal to the laser beam. A refractive index of 1.33 was used for the dispersed phase. A minimum of three repetitions were held for each treatment. The mass median aerodynamic diameter was 3.9 mm. It has to be noted that the dilution directions were followed as it was indicated by the company Ryujyu Science; however, a different nebulization system was used. Specifically, it Figure 6 . Sunmist jet-nebulizer, with a 10-ml residual cup.
was recommended that nebulization of 4-10 ml 5% glucose solution into the lungs should be performed in 15-30 min by 10 l min À 1 , use of a 2-MHz. We tested three different compressor nebulizer systems in our laboratory: (a) Invacare (Invacare GmbH -Alemannenstrabe 10, D-88316 Isny, Germany) (b) Sunmist and (c) Maxineb (Flexicare Medical Ltd., Mid Glamorgan, UK) with the mastersizer 2000, and it was observed that only the Sunmist was capable of delivering aerosol droplets of o5 mm (1 ml per 5 min). A droplet size of o5 mm is necessary as previously stated in the published literature in order to be properly deposited in the lung parenchyma. 74, 75 The aerosol was delivered in a nose through only sealed plastic cage specially designed and engineered for this experiment (Figure 7 ). Similar efforts of designing the system of administration have been made previously by other authors. 44 Specifically, the residual cap was connected to a specific receptor in the cage in order for the nose of the mouse to be directly at the site of the aerosol production ( Figure 6 ). The sealed cage had also a filter as a chimney in an effort to evaluate the amount of vector that was not inhaled; however, this parameter was not investigated and it will be used in future experiments. The cage that was specifically designed for this experiment was also approved by the Greek National Council for Animal Experimentation (Permission number. 482384/ 4146-13). (c) Green arrow shows nose-only reception; black arrow represents filter reception from the inside of the cage; there is also a valve that allows the aerosol only to leave the cage; yellow arrow represents receptions where the plastic wall attaches. (d) Black arrow represents the connection of the residual cup to the nose-only inlet and yellow arrow represents the nose-only inlet that can include the whole body of the BALBC mice (cage designed and engineered by Paul Zarogoulidis).
